Details for Patent: 10,525,033

Which drugs does patent 10,525,033 protect, and when does it expire?

Patent 10,525,033 protects BARHEMSYS and is included in one NDA.

This patent has fifty-two patent family members in twenty-six countries.

Summary for Patent: 10,525,033

Patent landscape, scope, and claims:

Title:	Use of amisulpride as an anti-emetic
Abstract:	Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.
Inventor(s):	Gilbert; Julian Clive (Cambridge, GB), Gristwood; Robert William (Cambridge, GB), Cooper; Nicola (Essex, GB), Fox; Gabriel (Cambridge, GB)
Assignee:	Acacia Pharma Limited (Duxford, Cambridge, GB)
Application Number:	16/105,268
Patent Claim Types: see list of patent claims	Composition; Dosage form;

Drugs Protected by US Patent 10,525,033

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Acacia	BARHEMSYS	amisulpride	SOLUTION;INTRAVENOUS	209510-001	Feb 26, 2020		RX	Yes	Yes	10,525,033		Y
Acacia	BARHEMSYS	amisulpride	SOLUTION;INTRAVENOUS	209510-002	Sep 1, 2020		RX	Yes	Yes	10,525,033		Y

Foreign Priority and PCT Information for Patent: 10,525,033

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	1004020.2	Mar 11, 2010

International Family Members for US Patent 10,525,033

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2011225898
Brazil	112012022746
Canada	2792392
China	102892407
Cyprus	1115485
Cyprus	1115487